Announced Fri, 14 Aug · 16:58 IST
Rubicon Research Q1FY27 Investor Presentation: Revenue up 51.6% YoY
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDFExplain this filing
RUBICON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+12.5%1-day move
₹1611.80
prior close
₹1700.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.5-3.7-2.8-2.7+12.5+11.1+9.2+7.1——————
Up moveDown movePending
AI summary
Rubicon Research Q1FY27 revenue rose 51.6% YoY to INR 5,343 Mn. EBITDA grew 64.6% to INR 1,312 Mn and PAT jumped 95.8% to INR 848 Mn. USD revenue up 32% YoY to $55 Mn. Operating EBITDA margin improved to 24.2%. Management raised FY27 margin guidance to at least 23% from earlier 22-23% range. Specialty products contributed 36% of gross profit. Acquired Arinna Lifesciences for INR 1,759 Mn and US-based InvaTech Pharma for $2.9 Mn.
Likely market impact
Strong Q1 with margin guidance upgrade signals positive outlook. US and India acquisitions expand specialty and CNS footprint.